Join Class Action »
Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of AnaptysBio, Inc. (NASDAQ: ANAB) from October 10, 2017 through November 7, 2019 (the “Class Period”). The lawsuit seeks to recover damages for AnaptysBio, Inc. investors under the federal securities laws.
If you bought AnaptysBio, Inc. securities between October 10, 2017 through November 7, 2019, and would like to join the action, please click “Join This Class Action,” above.
SHAREHOLDER ALERT: Zhang Investor Law Announces a Securities Class Action Lawsuit Against AnaptysBio, Inc – ANAB
New York, N.Y., March 26, 2020. Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of AnaptysBio, Inc. (NASDAQ: ANAB) between October 10, 2017 and November 7, 2019, inclusive (the “Class Period”).
To join the ANAB class action, go to http://zhanginvestorlaw.com/cases/anaptysbio-inc/ call Sophie Zhang, Esq. toll-free at 800-991-3756 or email firstname.lastname@example.org for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU NEED NOT BE A LEAD PLAINTIFF IN ORDER OBTAIN COMPENSATION.
According to the lawsuit, throughout the Class Period (1) important data from the Company’s Phase 2a trial in atopic dermatitis, including the timing and extent of patients’ use of topical corticosteroids as a rescue therapy during the study and whether any of the patients that utilized rescue therapy were classified as responders at a given time; (2) key information from the Company’s Phase 2a trial in peanut allergy, including patients’ average cumulative peanut dose tolerated at day 14 after the administration of etokimab or placebo as well as whether the Company’s decision to exclude 20% of the patients enrolled in the study from the interim analysis due to their mild symptoms was retrospective; and (3) as a result, Defendants’ positive statements about the efficacy and prospects of AnaptysBio’s lead drug asset, etokimab (formerly ANB020), in the treatment of atopic dermatitis and peanut allergy were materially false and/or misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 26, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://zhanginvestorlaw.com/cases/anaptysbio-inc/ or to discuss your rights or interests regarding this class action, please contact Sophie Zhang, Esq. of Zhang Investor Law toll free at 800-991-3756 or via e-mail at email@example.com.
Zhang Investor Law represents investors worldwide.